A law firm has launched a short‑report investigation into the proposed sale of Masimo Corporation to Danaher Corporation. The investigation, announced by Kahn Swick & Foti, LLC on April 8 2026, focuses on whether the $180.00 per share cash consideration is adequate and whether the sale process complied with regulatory and fiduciary standards.
The proposed transaction values Masimo at approximately $9.9 billion in all cash, offering shareholders a premium of about 38% over the company’s pre‑announcement trading price of $130.15. The deal would take Masimo private and place it under Danaher’s umbrella, where it would operate as a standalone business unit within Danaher’s diagnostics portfolio.
The investigation will examine the fairness of the offer and the adequacy of the $180.00 per share consideration. Analysts and investors are watching closely because the deal’s valuation and timing could affect shareholder approval and the likelihood of regulatory clearance. A finding of material deficiencies could prompt a reassessment of the offer price or delay the closing of the transaction.
Masimo’s recent financial performance provides context for the deal’s valuation. In Q4 2025, the company reported preliminary revenue of $411 million, up 12% year‑over‑year, and a non‑GAAP EPS of $1.16, missing analysts’ expectations of $1.49 by 22.15%. Full‑year 2025 revenue was $1,526.9 million, a 9% increase from the prior year. These results illustrate a company that has grown revenue but faced margin pressure and earnings misses, factors that may influence the perceived fairness of the $180 per share offer.
The sale follows a period of governance turbulence, including a proxy battle and the departure of former CEO Joe Kiani. Masimo’s current CEO, Katie Szyman, has expressed optimism about the company’s positioning and stated that joining Danaher would “continue our growth and momentum as the global leader in patient monitoring.” The acquisition is seen as a strategic fit for Danaher, which aims to strengthen its diagnostics segment and leverage its Danaher Business System to drive operational efficiency at Masimo.
The investigation’s outcome will be closely monitored by investors and regulators alike, as it could shape the final terms of the deal and the future trajectory of Masimo’s business under Danaher’s ownership.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.